12:00 AM
 | 
Oct 25, 1999
 |  BC Week In Review  |  Company News  |  Other News

Creative BioMolecules renal, musculoskeletal, neurological news

CBMI said it will reduce headcount from 70 to 43 and will focus on development of its morphogenic protein clinical candidates to treat stroke and renal...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >